Search clinical trials for: Ultravist (Iopromide, BAY86-4877)

Total 55 results

Bayer

Completed

A Study to Learn More About the Safety of Ultravist in Children and in the Elderly

Hypersensitivity

Germany
Bayer

Completed

PMS Study Ultravist-IMAGE, IoproMide (UltrAvist) to Gain Further Information on Tolerability and Safety in X-ray Examination (IMAGE)

Diagnostic Imaging

Poland, China, Germany, Hungary, Indonesia, Korea, Republic of, Malaysia, Saudi Arabia, Singapore, Thailand, Philippines, Taiwan, Italy, Moldova, Republic of, Romania, Russian Federation, Ukraine, Bosnia and Herzegovina, Pak... and more
Bayer

Completed

A Study, Called UV Population, to Learn More About the Safety of the Study Drug Ultravist, Which is Given to Get Clearer X-ray Pictures, in People of Different Sexes, Races, and From Different Countries/Regions

Contrast Enhanced X-ray Based Examination

Germany
Bayer

Completed

A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting (RIGHT)

Multidetector Computed Tomography | Angiography

China
Bayer

Completed

Observational Study of Ultravist in Patients Requiring CECT (INDEX)

Diagnostic Imaging

China
Bayer

Completed

Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid (UVIA)

Contrast Medium

Germany
Bayer

Completed

The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) (TRUST)

Angiocardiography

China
Chinese PLA General Hospital

Completed

A Safety Comparison of Iopromide and Iodixanol in Renal Impaired Patients (DIRECT)

Kidney Failure, Chronic

China
Yong Huo

Unknown

Renal Toxicity of Iodixanol and Iopromide in Patients With Renal Dysfunction (RIPE)

Kidney Failure, Chronic

China
University of Arizona

Terminated

An Early Phase Clinical Trial to Evaluate the Feasibility of CEST MRI in Patients With Early Stage Breast Cancer

Breast Cancer

United States
Seoul National University Hospital

Completed

Comparison of NEOVIST 370 INJ.(Iopromide 768.86mg) With Ultravist 370 INJ.(Iopromide 768.86mg) in Abdominal CT

Abdominal CT
Ospedale San Donato
Ospedale Le Scotte; Ospedale della Misericordia - Grosseto

Completed

Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI) (CONTRAST-AMI)

Acute Myocardial Infarction | Contrast Induced Nephropathy

Italy
Guerbet

Completed

Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography (X-ACT)

Coronary Artery Disease

Spain, France, Germany, Italy, Switzerland
Seoul National University Hospital

Unknown

Role of Perfusion CT in Pancreatic Cancer

Neuroendocrine Carcinoma of Pancreas | Adenocarcinoma, Pancreas

Korea, Republic of
Medical University of South Carolina
Bayer

Completed

VOLtage-based Contrast Media AdaptatioN in Coronary Computed Tomography Angiography (VOLCANIC-CTA)

Cardiovascular Diseases | Coronary Artery Disease

United States
Bayer

Completed

Gadobutrol Pharmacokinetic and Safety Study in Pediatric Subjects Aged <2 Years (Term Newborn Infants to Toddlers 23 Months of Age Inclusive)

Magnetic Resonance Imaging

United States, Canada, Germany
Bayer

Completed

Gadobutrol Enhanced MRA of the Renal Arteries (GRAMS)

Renal Artery Obstruction

Taiwan, United States, Korea, Republic of, France, Turkey, Switzerland, Austria, Poland, Brazil, Colombia, Germany, Czech Republic, Argentina
Bayer

Completed

Gadobutrol Enhanced MRA of the Supra-aortic Vessels (GEMSAV)

Carotid Stenosis

France, China, United States, Austria, Poland, Australia, Italy, Turkey, Germany, Korea, Republic of, Sweden, Switzerland, Czechia, Argentina
Bayer

Completed

GARDIAN, Gadovist in Routine Diagnostic Magnetic Resonance Imaging Administration in Non-selected Patients (GARDIAN)

Magnetic Resonance Imaging | Magnetic Resonance Angiography

Poland, China, France, Germany, Hungary, Korea, Republic of, South Africa, Spain, Thailand, Taiwan, Czech Republic, Hong Kong, Italy, Kazakhstan, Russian Federation, Bosnia and Herzegovina, Greece, Canada, Vietnam, Kyrgyzstan
Bayer

Completed

Patient Characteristics in Daily Radiological Practice of Gadovist® Application (PATRON)

Epidemiologic Factors

Germany
Bayer

Completed

Safety of Gadovist in Renally Impaired Patients (GRIP)

Fibrosis | Renal Impairment

Italy, Spain, Korea, Republic of, Germany, Canada, France, Austria, Thailand, Australia, Switzerland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar in Japanese Subjects for CNS Imaging

Magnetic Resonance Imaging

Japan
Bayer

Completed

Observational Study on the Safety and Tolerability of Gadobutrol (Gadovist) Among Filipino Patients in Magnetic Resonance Imaging

Magnetic Resonance Imaging

Philippines
Bayer

Completed

Gadobutrol Magnevist-controlled Body Study

Magnetic Resonance Imaging

China, Korea, Republic of, Japan
Bayer

Completed

A Study Called GUS to Understand How Much of the Contrast Agent Gadavist is Used and How Much is Wasted in Two Different Containers (Single-dose Vials and Imaging Bulk Packages ) in a Real-world Setting

Contrast Enhancement in Magnetic Resonance Imaging

United States
Bayer

Completed

Drug Use Investigation of Gadovist.

Magnetic Resonance Imaging | Image Enhancement

Japan
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast Magnetic Resonance Imaging (MRI) (GEMMA 2)

Breast Cancer

Spain, Canada, Taiwan, United States, India, Netherlands, Poland, Germany, Argentina
Bayer

Completed

Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI

Breast Cancer | Diagnostic Imaging

Italy, Korea, Republic of, Switzerland, Colombia, United States, Brazil, Germany, Finland, Argentina
Bayer

Completed

Gadobutrol / Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 2)

Coronary Artery Disease

United States, Canada, Singapore, Australia
Bayer

Completed

Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD) (GadaCAD 1)

Coronary Artery Disease

New Zealand, United Kingdom, United States, France, Germany, Korea, Republic of, Switzerland
Bayer

Completed

A Study of Magnetic Resonance Imaging (MRI) With Gadavist in Children

Magnetic Resonance Imaging

Sweden, Canada, Austria, Germany
Bayer

Completed

Myocardial Perfusion MRI

Magnetic Resonance Imaging | Myocardial Perfusion Imaging

Switzerland, Germany, Austria, Poland
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases

Korea, Republic of, United States, Colombia, China, Argentina
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients

Vascular Diseases

China
Bayer

Completed

Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients

Central Nervous System Diseases

China
Bayer

Completed

Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.

Neoplastic CNS Lesions

Italy
Bayer

Completed

SH L 562BB Phase II/III Dose Justification and Gadoteridol-controlled Comparative Study

Brain Metastases

Japan
Bayer

Completed

Primovist Post-marketing Surveillance in Japan (PRIMOVIST)

Diagnostic Imaging

Japan
Bayer

Completed

Primovist / Eovist in Renally Impaired Patients (PERI)

Contrast Media

United States, Germany, Italy, Korea, Republic of, Austria, Thailand, Australia, Spain, United Kingdom
Bayer

Completed

Dose Finding Study of Gadavist in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)

Brain Diseases | Spinal Cord Diseases

United States, Colombia, Argentina, Brazil
Bayer

Completed

Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging

Central Nervous System Diseases | Diagnostic Imaging

United States, Australia, Germany, Switzerland, Japan, Austria, Colombia, India
GE Healthcare
Bayer; Guerbet/Liebel-Flarsheim

Withdrawn

Pediatric Risk of Hypothyroidism With Iodinated Contrast Media

Hypothyroidism
Bayer

Completed

Efficacy and Safety of Primovist in Chinese Patients

Known or Suspected Focal Liver Lesions

China
Bayer

Completed

Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Carcinoma | Liver Neoplasms | Adenoma | Liver Abscess

United States, Japan, Singapore, Taiwan, Italy
Bayer

Completed

Primovist Regulatory Post Marketing Surveillance (PMS)

Liver

Korea, Republic of
Bayer

Terminated

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Magnetic Resonance Imaging

United States
Guerbet
Bayer AG (Sponsor); Bracco (Sponsor); GEHC (Sponsor)

Recruiting

Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years (ODYSSEY)

Cognitive Function | Motor Function | Contrast Media

United States, Korea, Republic of, Italy, Brazil, Canada, Russian Federation
Bayer

Completed

Comparison of Gadovist 75% Standard Dose to Dotarem at Full Standard Dose (LEADER 75)

Magnetic Resonance Imaging

United States, Korea, Republic of, France, Germany, Italy, Switzerland, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Novel MRI Techniques for the Characterization and Treatment Assessment of High Grade Brain Lesions

Lymphoma | Brain Neoplasm | Metastatic Malignant Neoplasm in the Brain | Recurrent Malignant Brain Neoplasm

United States
Bayer

Completed

FC Patch Low: Metabolism Study

Contraception

Germany

Search clinical trials for: Ultravist (Iopromide, BAY86-4877)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations